TET2-mutant clonal hematopoiesis and risk of gout.
Agrawal M, Niroula A, Cunin P, McConkey M, Shkolnik V, Kim PG, Wong WJ, Weeks LD, Lin AE, Miller PG, Gibson CJ, Sekar A, Schaefer IM, Neuberg D, Stone RM, Bick AG, Uddin MM, Griffin GK, Jaiswal S, Natarajan P, Nigrovic PA, Rao DA, Ebert BL.
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM; FAST Study Group.
Lancet. 2020 Nov 28;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0. Epub 2020 Nov 9.
PMID:33181081
Lead nephropathy, gout, and hypertension.
Batuman V.
Am J Med Sci. 1993 Apr;305(4):241-7. doi: 10.1097/00000441-199304000-00008.
PMID:8475950
Tophaceous Gout.
Liu Y, Jiao Y.
Clin Case Rep. 2025 Feb 20;13(2):e70262. doi: 10.1002/ccr3.70262. eCollection 2025 Feb.
PMID:39991539
Hyperuricemia and Cardiovascular Disease.
Zhang S, Wang Y, Cheng J, Huangfu N, Zhao R, Xu Z, Zhang F, Zheng W, Zhang D.